Consensus Bolt Biotherapeutics, Inc.

Stocks

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2026-08-14 EDT			5-day change	1st Jan Change
3.350 ^USD	+4.36%		-17.28%	-38.73%

08-11	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-12	Bolt Biotherapeutics reports first quarter 2026 financial results	RE

Evolution of the Average Target: Bolt Biotherapeutics, Inc.

Evolution of the Target Price: Bolt Biotherapeutics, Inc.

Changes in Analyst Recommendations: Bolt Biotherapeutics, Inc.

53ae5608d2.CWMUCffVNKB-Rs0riGBxaQKX-rFbjwPCZ-25jGsiPUo.XBFhcMChZtYPPJtayQYFLC_InuQ6zE6vBtro4TFabChjPFZtsrdG5ysTiA~47bf30d1682e50f58851c9062ad2a61d

Analysts' recommendations: Bolt Biotherapeutics, Inc.

24-05-15	Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	MT
24-05-15	Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
24-05-15	HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
24-05-15	Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
23-05-12	SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4	MT
23-01-24	Morgan Stanley Cuts Price Target on Bolt Biotherapeutics to $3 From $5, Maintains Equal-Weight Rating	MT
22-10-04	HC Wainwright Starts Bolt Biotherapeutics at Buy With $8 Price Target	MT
22-08-11	Stifel Nicolaus Lowers Price Target for Bolt Biotherapeutics to $7 From $13, Maintains Buy Rating	MT
22-08-11	SVB Securities Downgrades Bolt Biotherapeutics to Market Perform from Outperform, Adjusts Price Target to $4 from $8	MT
22-05-17	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalweight Rating	MT
22-05-16	Stifel Adjusts Bolt Biotherapeutics' Price Target to $13 From $16, Reiterates Buy Rating	MT
22-02-01	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $7 from $11, Keeps Equalweight Rating	MT
22-01-06	Morgan Stanley Downgrades Bolt Biotherapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $45	MT
21-12-07	Stifel Adjusts Bolt Biotherapeutics' Price Target to $19 From $34, Reiterates Buy Rating	MT
21-11-10	SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $33 from $35, Keeps Outperform Rating	MT
21-08-16	Bolt Biotherapeutics : SVB Leerink Raises Bolt Biotherapeutics' Price Target to $35 From $34, Maintains Outperform Rating	MT
21-04-06	Bolt Biotherapeutics : SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $37 From $36, Maintains Outperform Rating	MT
21-03-02	Bolt Biotherapeutics : Morgan Stanley Starts Bolt Biotherapeutics at Overweight With $45 Price Target	MT
21-03-02	Bolt Biotherapeutics : SVB Leerink Starts Bolt Biotherapeutics at Outperform With $36 Price Target	MT
21-03-02	Bolt Biotherapeutics : Stifel Starts Bolt Biotherapeutics at Buy With $40 Price Target	MT
21-03-02	Bolt Biotherapeutics : Guggenheim Starts Bolt Biotherapeutics at Buy With $42 Price Target	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
BOLT BIOTHERAPEUTICS, INC.			+765.67%
WUXI APPTEC CO., LTD.			+14.63%
ARGENX SE	-	-	+45.47%
INSMED INCORPORATED			+61.67%
WUXI BIOLOGICS (CAYMAN) INC.			+5.3%
BIONTECH SE			+29.48%
PHARMAESSENTIA CORPORATION			-18.91%
GENMAB A/S			+18.92%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.			+9.52%
EXELIXIS, INC.			+3.31%
Average			+93.51%
Weighted average by Cap.			+23.11%